TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Digestive System Department
Division of General Internal Medicine
更新時間：2023-09-19
劉志銘LIOU, JYH-MING
- Co-Principal Investigator
- Clinical Trial Experience (year) 17 years 9 個月
-
jyhmingliou@gmail.com
Publication
28Publications
1
Liou JM, Jiang XT, Chen CC, Luo JC, Bair MJ, Chen PY, Chou CK, Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Kuo CC, Chiu MC, Chen CY, Shun CT, Hu WH, Tsai MH, Hsu YC, Tseng CH, Chang CY, Lin JT, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):228-241.
2
Chiang TH, Chen CC, Tseng PH, Liou JM, Wu MS, Shun CT, Lee YC, Graham DY. Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study. Helicobacter. 2021 Jun;26(3):e12801. doi: 10.1111/hel.12801. Epub 2021 Mar 19. PMID: 33740276.
3
Yao M, Liao SL, Lin CW, Wang CP, Ma WL, Wei YH, Liou JM, Wang IJ, Cheng AL, Kuo SH. First-line antibiotic treatment in patients with localized extragastric mucosa-associated lymphoid tissue lymphoma.EJHaem. 2022 Nov 6;4(1):55-66.
4
Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021 Jan-Dec;13(1):1-22. doi: 10.1080/19490976.2021.1909459. PMID: 33938378; PMCID: PMC8096336.
5
Tseng YY, Liou JM, Cheng WC, Hsu JT, Hsu TL, Wu MS, Wong CH.Combating multidrug-resistant Helicobacter pylori with moenomycin A in combination with clarithromycin or metronidazole. Front Chem. 2022 Oct 19;10:897578.
6
Graham DY, Liou JM. Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship. Clin Gastroenterol Hepatol. 2021 Mar 26:S1542-3565(21)00336-0. doi: 10.1016/j.cgh.2021.03.026. Epub ahead of print. PMID: 33775895; PMCID: PMC8464630.
7
Chen MJ, Bair MJ, Chen PY, Lee JY, Yang TH, Fang YJ, Chen CC, Chang AT, Hsiao WD, Yu JJ, Kuo CC, Chiu MC, Lin KP, Tsai MH, Hsu YC, Chou CK, Chen CY, Lin JT, Lee YC, Wu MS, Liou JM; for the Taiwan Gastrointestinal Disease and Helicobacter Consortium. Declining trends of prevalence of Helicobacter pylori infection and incidence of gastric cancer in Taiwan: An updated cross-sectional survey and meta-analysis.Helicobacter. 2022 Oct;27(5):e12914.
8
Chen MJ, Fang YJ, Wu MS, Chen CC, Chen YN, Yu CC, Kuo CC, Chiu MC, Hu WH, Tsai MH, Hsieh CL, Chen HH, Bair MJ, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan. J Gastroenterol Hepatol. 2020 Feb;35(2):233-240. doi: 10.1111/jgh.14828. Epub 2019 Sep 3. PMID: 31408909.
9
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study group.Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report.Gut. 2022 Aug 8:gutjnl-2022-327745.
10
Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Chen CC, Lee JY, Yang TH, Luo JC, Chen CY, Hsu WF, Chen YN, Wu JY, Lin JT, Lu TP, Chuang EY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019 Oct;19(10):1109-1120. doi: 10.1016/S1473-3099(19)30272-5. PMID: 31559966.
